| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 2,050 | 1,520 | 230 | 170 | 940 |
| Sales Growth | +34.87% | +560.87% | +35.29% | -81.91% | -92.46% |
| Net Income | -34,030 | -31,060 | -30,430 | -5,660 | -42,990 |
| Net Income Growth | -9.56% | -2.07% | -437.63% | +86.83% | +19.79% |
Lumos Pharma Inc (LUMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Lumos Pharma Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's product pipeline consists of LUM-201 which is in clinical stage. Lumos Pharma Inc., formerly known as NewLink Genetics Corporation, is based in AUSTIN, Texas.
Fiscal Year End Date: 12/31